Controversy over statins for primary prevention: Cochrane review gets people talking…

By February 7, 2011Pharma Beat
Meducom Blog

The recently published Cochrane review on the benefits of statins for primary prevention of coronary heart disease has stirred up quite a bit of discussion this week. In contrast to a meta-analysis published last year in the Lancet by the Cholesterol Treatment Trialists’ Collaboration, Taylor and colleagues concluded that there is not enough evidence to recommend the widespread use of statins for primary prevention in patients with no prior history of cardiovascular disease.

While this systematic review may ultimately have little impact on clinical practice, this recent controversy highlights how challenging the management of low-risk patients in the primary prevention setting can be for physicians. Balancing potential benefits over risks is particularly difficult when treating patients who may develop the disease based on their risk factor profile.

Pages: 1 2